Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24039033 | 0.89 | POLB (0.61) | KMT2APOLBKDM4EALDH1A1EIF4H | |
| SCHEMBL23495365 | 0.71 | KDM4E (0.71) | KMT2AKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL29436195 | 0.71 | KDM4E (0.71) | KMT2AKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL29436189 | 0.70 | LMNA (0.67) | KMT2APOLBKDM4EALDH1A1LMNA | |
| SCHEMBL23495356 | 0.70 | LMNA (0.67) | KMT2APOLBKDM4EALDH1A1LMNA | |
| SCHEMBL29436239 | 0.70 | LMNA (0.67) | KMT2APOLBKDM4EALDH1A1LMNA | |
| SCHEMBL23495302 | 0.70 | LMNA (0.67) | KMT2APOLBKDM4EALDH1A1LMNA | |
| SCHEMBL23853032 | 0.70 | KMT2A (0.57) | KMT2APOLBKDM4EALDH1A1MAPT | |
| SCHEMBL25525653 | 0.69 | MEN1 (0.64) | KMT2APOLBKDM4ELMNAGLA | |
| SCHEMBL29436206 | 0.68 | ALDH1A1 (0.69) | POLBKDM4EALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | KMT2A 3926/4885POLB 1270/4885KDM4E 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.